Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152631 · ClinicalTrials.gov registry record · Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT02152631: Active Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company.
NCT02152631 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 453 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152631, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
Primary Outcome
OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Erlotinib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California - San Diego - La Jolla
- Loma Linda University School of Medicine - Loma Linda
- CBCC Global Research, Inc. - Los Angeles
- Central Coast Medical Oncology Corporation - Los Angeles
- Fort Wayne Oncology & Hematology - Los Angeles
- SMO TRIO -Translational Research - Los Angeles
- St. Joseph Heritage Medical Group - Los Angeles
- UCLA Department of Medicine-Hematology/Oncology - Los Angeles
- Cancer Care Associates Medical Group - Los Angeles
- Dignity Health Care Institute - Sacramento
Colorado
- Alegent Immanuel Cancer Center - Englewood
- Jewish Hospital - Englewood
- Oncology Hematology West - Englewood
- SMO Catholic Health Initiatives - Englewood
- St Joseph Cancer Center - Englewood
- St. Francis Medical Center - Englewood
Arkansas
- Highlands Oncology Group - Fayetteville
- St. Bernards Medical Center - Jonesboro
Delaware
- Medical Oncology Hematology Consultants - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2014-10-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT02152631 still lists
NCT02152631 is an interventional study that assigns participants to a tested intervention. The registered 453 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT02152631 names 20 study sites across 4 states, led by California, Colorado, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02152631 about?
NCT02152631 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer". The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
What is the current status of trial NCT02152631?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2014-10-03. Estimated completion is 2026-12.
What conditions does trial NCT02152631 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02152631?
The interventions under investigation include: Abemaciclib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT02152631?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152631 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02152631's enrollment target sits among peer trials
453 88th of 454 higher than 367 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI